Aclaris shares surge on licensing deal valued at up to nearly $1 billion
Nov 18, 2024
Aclaris' deal completes a strategic review process the company initiated at the start of the year after experiencing setbacks with two new drug candidates.
https://www.bizjournals.com/philadelphia/news/2024/11/18/aclaris-malvern-biosion-licensing-deal-stock-deal.html?ana=RSS&s=article_search
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service